Discovery Fast Track Challenge safeguards your IP.
A critical aspect throughout this Challenge is respect for the intellectual property rights of investigators, institutions and GSK.
Applying investigators (in conjunction with their institution) have ultimate control over which proposals to submit for evaluation. In order to enter the Challenge, investigators must first create a password-protected account on the Challenge website so that only they can access and manage their application.
We require that investigators consult with their institution’s Technology Transfer Office (TTO) before applying to the Challenge.
When an application is submitted, an institution TTO staff member is required to provide approval via email for each application in order to allow our GSK judges to start their review. Until this email confirmation is received from an institution’s TTO, our GSK judges will be unable to view the investigator's application. Please review the TTO guidelines for more information.
All information submitted by the investigator in the initial application must be non-confidential. By submitting an application, the investigator:
- Waives any claims of confidentiality to the initial application and agrees that GSK shall be free to use the application for informational purposes as outlined in the Challenge Terms and Conditions.
- Agrees that they have received endorsement from the appropriate persons/groups/departments at their institution (including the Technology Transfer Office) to submit the initial application to the Challenge. We will ensure that the judges will not discuss, use, or convey any information they read in a finalist’s entry, or hear in the presentation, with any other person(s) outside of the judging process.
Finalists will be requested to provide a 5-page proposal and enter, with their institution, into the Challenge Confidential Disclosure Agreement (CDA). A CDA is intended for use when confidential information is being shared between two parties and is not appropriate when only non-confidential information is being shared.
Finalists and their GSK mentor will initiate a due diligence process in order to ensure that the research and associated technology of the reagents and assays is unencumbered by any institutional or external obligations and that the proposed work is potentially amenable to screening using the GSK encoded library technology. This diligence will include determining whether other individuals have contributed in a material way to the research in order to ensure they are acknowledged and have approved the submission of the concept.
As part of the Challenge, winners or a member of their team, should they wish to, will have the opportunity to work alongside GSK scientists on their target. As such, visiting scientists will be required to sign a Challenge Visiting Scientist Agreement for the purposes of working at GSK.
The finalists and their respective TTOs will be asked to initiate discussions to confirm that the institution can execute the Challenge Material Transfer Agreement (MTA) and Challenge Visiting Scientist Agreement. This early action will enable sufficient time for the institution to review and understand the MTA and Visiting Scientist Agreement before winners are selected.
The purpose of the MTA is to facilitate transfer of reagents and assays to GSK to enable screening of the investigator’s target. The MTA also governs the “next steps” that may result from the screening process, including the potential sharing of structures for tool compounds from GSK to the institution, and protects the IP rights of both parties.
Once winners are selected, our offer to screen an investigator’s target is conditional upon execution of the Challenge MTA and Visiting Scientist Agreement by the winner’s institution.